Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Research objectives: MT-I is primarily researched for its ability to increase tanning and tolerance to UV/sunlight
The Phase 2 trial indicated that retatrutide is similar in terms of safety and side effects to tirzepatide and semaglutide, and the TRIUMPH-1 Phase 3 trial confirmed a manageable safety profile at all doses tested
Purpose-built for physicians Oral quadruple receptor agonist confers weight loss with minimal GI adverse events Key takeaways: Adults with obesity lost 11.3% of body weight with 120 mg NA-931 and 13.8% with 150 mg NA-931 at 13 weeks
Consumer GLP-1 patches have not met these criteria
ODS, Office of Dietary Supplements, National Institutes of Health
US$ 26.36
US$ 20.30
US$ 23.02
US$ 25.89
